Biotech · Private company
Alkahest, Inc.
Track this companyFree. Adds Alkahest, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials90 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline17
- AfliberceptPhase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- AKST4290Phase 2 · Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- AKST4290Phase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- AKST4290Phase 2 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- GRF6019Phase 2 · Severe Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- GRF6019Phase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- GRF6021Phase 2 · Postoperative RecoveryClinicalTrials.gov · fetched Nov 12, 2026
- GRF6021Phase 2 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AKST1210Cognitive ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- AKST1210 S-15 at 250 mL/minEnd-Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AKST1210 S-15 at 450 mL/minEnd-Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AKST1210 S-25 at 250 mL/minEnd-Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AKST1210 S-25 at 450 mL/minEnd-Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AKST1210 S-35 at 250 mL/minEnd-Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AKST1210 S-35 at 450 mL/minEnd-Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- HemodialysisCognitive ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- Sham Control (No Intervention)Cognitive ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)PHASE2 · TERMINATED · started Aug 17, 2021ClinicalTrials.gov NCT05038020 · fetched Nov 12, 2026
- Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on HemodialysisNA · COMPLETED · started Mar 11, 2021ClinicalTrials.gov NCT04985383 · fetched Nov 12, 2026
- A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive ImpairmentNA · COMPLETED · started Apr 28, 2020ClinicalTrials.gov NCT04527328 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMDPHASE2 · COMPLETED · started Jan 28, 2020ClinicalTrials.gov NCT04331730 · fetched Nov 12, 2026
- Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic TreatmentPHASE2 · COMPLETED · started Jan 16, 2020ClinicalTrials.gov NCT04369430 · fetched Nov 12, 2026
- A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee ArthroplastyPHASE2 · COMPLETED · started Jul 12, 2019ClinicalTrials.gov NCT03981419 · fetched Nov 12, 2026
- A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's DiseasePHASE2 · COMPLETED · started Jan 15, 2019ClinicalTrials.gov NCT03765762 · fetched Nov 12, 2026
- A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive ImpairmentPHASE2 · COMPLETED · started Nov 12, 2018ClinicalTrials.gov NCT03713957 · fetched Nov 12, 2026
- A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's DiseasePHASE2 · COMPLETED · started Apr 16, 2018ClinicalTrials.gov NCT03520998 · fetched Nov 12, 2026